Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
ATLANTA, May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019.
Mr. Eiswirth’s presentation will be held at 2:00 PM PT in Room 9 of the Beverly Hilton Hotel, 9876 Wilshire Blvd. in Beverly Hills, Calif. Investors interested in one-on-one meetings should contact the conference organizers at conference@brileyfbr.com.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For Investor Inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com |
Latest Health & Supplement Reviews
- YuSleep Reviews (EXPOSED) Doctor Explains Deep Sleep Benefits, Hidden Risks & Real Consumers Results In 2026
- Neuro Energizer Reviews and Complaints 2026: How This Neuro-Sonic Breakthrough Is Reshaping Cognitive Therapy, Memory & Daily Focus
- Gluco6 Reviews and Complaints (March 2026) Real User Data on Natural Blood Sugar Balance and Glucose Stability